Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : TELK -- Telik, Inc. -- Ignore unavailable to you. Want to Upgrade?

To: tuck who wrote (469)	12/5/2004 7:30:33 PM
From: former_pgs	Read Replies (1) \| Respond to of 887

fwiw... The November 5th Prudential report on Telik by Jason Zhang now says that their most recent survey for ASSIST-1 enrollment suggests 350 patients enrolled. In his October 20 ahem research report, Zhang said that his limited survey at the time suggested 59 patients enrolled. Good work Jason, in case you're reading this. He also goes on to state in his November 5th report that the ASSIST-1 trial may fail to meet it's primary survival endpoint. A cancer trial failing to meet a survival endpoint? Shocking! Absolutely shocking! Anyone well versed in MDS care to comment on the playing field right now? I must admit to some laziness in having to tackle the research behind this indication.